Quotient Limited (QTNT: NASDAQ) Investor Relations Material

Overview

Quotient, a commercial-stage diagnostics company with over 30 years of experience in transfusion diagnostics, has developed a proprietary multiplex microarray technology called MosaiQ that aims to reshape the way diagnostics is practiced. MosaiQ is the world’s first fully automated, consolidated testing platform that offers multiple tests across different modalities, potentially improving clinical practice, increasing efficiencies, and delivering significant workflow improvements and operational cost savings to laboratories around the world. In response to the COVID-19 pandemic, Quotient developed the MosaiQ COVID-19 Antibody Microarray, which is CE marked and has received an Emergency Use Authorization from the U.S. FDA. The COVID-19 antibody test is currently available for distribution in the U.S., the EU, the UK, and Switzerland. Quotient's operations are based in Switzerland, Scotland, and Pennsylvania.